Browsing Tag
AACR 2026
3 posts
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
What AACR 2026 could reveal about Immunocore Holdings plc’s long-term immunotherapy durability (NASDAQ: IMCR)
Can Immunocore’s five-year KIMMTRAK data reshape oncology expectations? Discover the strategic, clinical, and investor implications now.
Antengene deepens oncology ambitions with three next-generation ADC and T-cell engager programs at AACR 2026
Discover how Antengene Corporation Limited’s AACR 2026 oncology presentations could reshape its pipeline strategy and investor outlook. Read the full analysis.